Atlas Analytics · Most cited CFR sections
Most Prevalent CFRs by GxP and Industry: the 21 CFR sections FDA cites most
21 CFR 211.22(d), which requires the quality unit's procedures to be written and followed, was the most cited section in FDA inspections in 2024 in the Atlas dataset, with 175 citations. 211.192, investigation of discrepancies, followed with 136, then 211.100(a), written production procedures, with 117.
Atlas dataset of FDA inspection citations · January 2019 to March 2025 · all GxP areas and industries · figures read October 14, 2026
Most Prevalent CFRs by GxP and Industry
175
211.22(d) citations, 2024
136
211.192 citations, 2024
9 of 10
Top sections from Part 211
+14%
211.22(d), 2023 to 2024
21 CFR 211.22(d) citations by year
Most cited sections, 2024
- 21 CFR 211.22(d)Quality unit procedures175
- 21 CFR 211.192Investigation of discrepancies136
- 21 CFR 211.100(a)Written production procedures117
- 21 CFR 312.60Clinical investigator duties96
- 21 CFR 211.160(b)Laboratory controls95
Sections 6 to 10 and every other year
Most cited sections, 2023
- 21 CFR 211.192Investigation of discrepancies159
- 21 CFR 211.22(d)Quality unit procedures154
- 21 CFR 211.100(a)Written production procedures99
- 21 CFR 211.160(b)Laboratory controls89
- 21 CFR 211.63Equipment design and size76
Sections 6 to 10
Top sections by GxP area
In the complete dashboard
GMP, GCP, GLP, IRB and pharmacovigilance citations compared.
Top sections by industry
In the complete dashboard
Human drugs, biologics, devices, foods, animal products and tobacco.
Complete dashboard
Get the full dashboard for your team
This page shows a free window. Share your work email and our team will send access to the complete dashboard, including:
- Every year from 2019, plus early 2025
- Sections 6 to 10 in every year
- Filters by GxP area: GMP, GCP, GLP, IRB and pharmacovigilance
- Filters by industry and country
- The detail page with section-level trends
The most cited 21 CFR sections in 2024
Nine of the ten most cited sections come from 21 CFR Part 211, the drug GMP rule. The exception is 21 CFR 312.60, which sets out a clinical investigator's duties and sits fourth in 2024 with 96 citations.
211.22(d) overtook 211.192 in 2024. When investigators cite the quality unit's procedures, they usually find the procedures exist but are not followed, which our post on documentation failures the FDA flagged in 2024 and 2025 explores with examples.
| Section | What it covers | 2023 | 2024 |
|---|---|---|---|
| 21 CFR 211.22(d) | Quality control unit responsibilities and procedures | 154 | 175 |
| 21 CFR 211.192 | Production record review and investigation of discrepancies | 159 | 136 |
| 21 CFR 211.100(a) | Written procedures for production and process control | 99 | 117 |
| 21 CFR 312.60 | General responsibilities of clinical investigators | 73 | 96 |
| 21 CFR 211.160(b) | Scientifically sound laboratory controls | 89 | 95 |
What the trend means for an inspection this year
A quality unit that cannot show it enforces its own procedures is now the single most cited gap. Before an inspection, check that every deviation has a closed investigation and that batch records match the current procedure. Our guides on how to address and prevent Form 483 observations and effective Form 483 responses cover the remediation.
Each section links to real observations in the FDA Form 483 database, where you can read the exact wording investigators used.
| Section | 2023 | 2024 | Change |
|---|---|---|---|
| 21 CFR 211.22(d) | 154 | 175 | +14% |
| 21 CFR 211.192 | 159 | 136 | -14% |
Frequently asked questions
What is the most cited 21 CFR section in FDA inspections?
In 2024 it was 21 CFR 211.22(d), quality control unit procedures, with 175 citations in the Atlas dataset. In 2023 it was 21 CFR 211.192, investigation of discrepancies, with 159. The two have swapped places at the top since 2019.
What does 21 CFR 211.22(d) require?
It requires the responsibilities and procedures of the quality control unit to be in writing and to be followed. Investigators cite it when a firm has procedures on paper but cannot show they are used, for example when deviations are closed without the review the procedure demands.
What does 21 CFR 211.192 cover?
21 CFR 211.192 requires production and control records to be reviewed, and any unexplained discrepancy or failure to meet specifications to be thoroughly investigated, with conclusions and follow-up documented. It is the classic citation for weak out of specification investigations. See understanding OOS results.
Why does 21 CFR 312.60 appear among drug GMP sections?
21 CFR 312.60 covers clinical investigators, who must follow the investigational plan, protect subjects and keep control of the drug. Clinical site inspections under the bioresearch monitoring program cite it often, which is why it ranks fourth in 2024 with 96 citations.
How do I get the full CFR citation data?
Enter your work email in the dashboard above. The full view adds every year from 2019, sections 6 to 10, and filters by GxP area, industry and country. Our team reviews each request and replies by email.

